Literature DB >> 31308812

Effect of Korean Red Ginseng in individuals exposed to high stress levels: a 6-week, double-blind, randomized, placebo-controlled trial.

Ji Hyun Baek1, Jung-Yoon Heo1, Maurizio Fava2, David Mischoulon2, Kwan Woo Choi1, Eun Jin Na1, Hana Cho3, Hong Jin Jeon1,4.   

Abstract

BACKGROUND: To investigate the neurobiological evidence supporting the adaptogenic effects of Korean Red Ginseng in reducing the harmful consequences of stress using a double-blind, placebo-controlled trial.
METHOD: Sixty-three subjects with high stress levels were randomized to receive an orally administered, double-blind, 6-week treatment with Korean Red Ginseng (n = 32) or placebo (n = 31). All participants underwent a comprehensive psychological evaluation using Beck Depression Inventory and Stress Response Inventory, cognitive evaluation using the continuous performance test, biological evaluation by measuring blood levels of lipids, catecholamines, inflammation markers, and heart rate variability at baseline and after 6 weeks.
RESULTS: At baseline, both groups showed no significant differences in age, sex, years of education, Beck Depression Inventory, and Stress Response Inventory. After 6 weeks, triglyceride levels were significantly increased within the normal limit in theKorean Red Ginseng group (F = 4.11, p = 0.048), and the epinephrine level was decreased in this group (F = 4,35, p = 0.043). The triglyceride increase was significantly associated with epinephrine decrease (B = -0.087, p = 0.041), suggesting that Korean Red Ginseng may stabilize the sympathetic nervous system. In addition, we detected a significant group by time effect in the visually controlled continuous performance test, suggesting positive effects of Korean Red Ginseng on cognition.
CONCLUSION: Korean Red Ginseng might help to stabilize the sympathetic nervous system and improve cognition in individuals with high stress.

Entities:  

Keywords:  Adaptogenic effect; Epinephrine; Korean Red Ginseng; Stress management; Triglyceride

Year:  2018        PMID: 31308812      PMCID: PMC6606819          DOI: 10.1016/j.jgr.2018.03.001

Source DB:  PubMed          Journal:  J Ginseng Res        ISSN: 1226-8453            Impact factor:   6.060


Introduction

Korean Red Ginseng (KRG; heat-processed Panax ginseng) has long been recognized as a traditional natural medicine for the goodness of physical and mental health in Far East Asia. Traditionally, it is believed to possess equilibrating, tonic, antistress, and adaptogenic actions. It remains one of the best-selling herbal products. Animal and preclinical studies have confirmed the neuromodulatory [1], neuroprotective [2], [3], [4], and antiinflammatory effects [5], [6], [7], which may be associated with antistress activity. However, there is little biological evidence underlying the adaptogenic effects, with no published double-blind randomized controlled trials (RCTs). This is the first double-blind RCT to explore the biological evidence supporting the adaptogenic effects of KRG. We compared the perceived stress levels, cognitive functions, and biological markers associated with stress in individuals with serious psychological distress (i.e., high-risk group). The high-risk group was randomized to 6 weeks of treatment with KRG or placebo. We investigated if administration of KRG improved the aforementioned variables.

Methods

Participants

We recruited nurses and fire fighters, members of two high-stress occupations, who aged 20–60 years. They responded to an advertisement concerning stress management with KRG. After explaining the purpose and procedures, participants who provided informed consent were included. Women of childbearing potential or those who were pregnant who had serious or unstable medical illness, past history of psychiatric illnesses, premenstrual syndrome, and clinically significant depression defined as Beck Depression Inventory (BDI) score ≥30 were excluded from the study. This study was approved by the Institutional Review Board of the Samsung Medical Center. After the screening interview, the stress response inventory (SRI) and the BDI were administered to select the high-stress group. The SRI is a widely used and valid measure of psychological, physical, cognitive, and behavioral stress responses in clinical practice [8]. It comprises 26 questions with responses measured on a 5-point Likert scale. The cutoff score to define high-stress individuals is ≥81 points. The BDI [9] is a popular measure to evaluate the severity and patterns of depressive symptoms based on 21 questions. Each question is used to measure the symptom severity on a 4-point Likert scale. We used the standardized Korean translated version [10], which has high sensitivity and reliability. The cutoff score to define high-stress individuals was ≥10 points, which indicates mild depression. Sixty-three of 100 screened participants (57.1% female; mean ± SD age = 40.4 ± 1.5 years) met the criteria for the high-stress group.

Study process

Preparation of Korean Red Ginseng

Korean Red Ginseng (KRG) powder was manufactured by Korea Ginseng Corporation, Seoul, Korea, from roots of a 6-year-old red ginseng, Panax ginseng Meyer, harvested in the Republic of Korea. KRG was prepared by steaming fresh ginseng at 90–100°C for 3 h and drying at 50–80°C. KRG powder was prepared from ground red ginseng. In our study, we used the KRG capsule (LAX-101), which contains 500 mg of KRG powder per capsule. KRG used in our study was analyzed by high-performance liquid chromatography. KRG extract contained major ginsenosides as follows: Rb1, 6.44 mg/g; Rb2, 2.25 mg/g; Rc, 2.68 mg/g; Rd, 0.50 mg/g; Re, 2.08 mg/g; Rf, 0.89 mg/g; Rg1, 3.21 mg/g; Rg2, 0.29 mg/g; Rg3, 0.18 mg/g; and other minor ginsenosides.

Baseline evaluation

All participants underwent comprehensive psychological, cognitive, and biological evaluations. For the psychological evaluation, the Perceived Stress Scale (PSS) [11] was used to measure the degree of individually perceived stress. The PSS contains 10 questions with responses measured using a 5-point Likert scale. We used the Korean version of PSS [12], which has excellent reliability and validity. The Profile of Mood States [13] was used to evaluate the mood status during the preceding week. The Profile of Mood States is a self-reported questionnaire comprising 65 questions that evaluate six dimensions, including tension or anxiety, anger or hostility, vigor or activity, fatigue or inertia, depression or dejection, and confusion or bewilderment, using a 5-point scale. The Sheehan Disability Scale [14] was used to evaluate the degree of functional impairment. The Sheehan Disability Scale comprises three questions with responses measured using an 11-point Likert scale. The tool explores functional levels at work/school, social, and family life. The cognitive evaluation involved the visual and auditory controlled continuous performance test (CPT), which was administered to evaluate attention and memory. The test takes 10 min to complete. In addition, the subjective cognitive impairment was assessed using the following question that was validated in a previous study [15]: “Do you have complaints about your memory?” Answers were coded in four categories (no; sometimes, but it is no problem; yes, it is a problem; yes, it is a serious problem). The biological evaluation involved determination of height and weight; vital signs, including blood pressure and heart rate; catecholamines, including norepinephrine and epinephrine; inflammatory factors, including interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-10, IL-12, interferon-gamma, tumor necrosis factor-alpha, and C-reactive protein; lipid levels, including high-density lipoprotein, low-density lipoprotein, triglycerides, and total cholesterol; and fasting blood sugar and HbA1c levels. Blood samples were drawn after 30 min of rest. Study flow diagram.

Randomization and evaluations (Fig. 1)

Sixty-three participants (57.1% female; mean ± SD age 40.4 ± 1.5 years) were randomly assigned after being considered eligible by a study clinician at the screening visit. Randomization was performed using the Excel program. A research coordinator conducted the randomization process. All study clinicians and participants remained blinded to the assignment for the duration of the study. Participants received treatment (four capsules per day taken twice daily) of either 2 g/day of KRG (LAX-101) or placebo for 6 weeks. We selected the dosage of 2 g/day based on the previous study [16]. Packaging, storing, and handling conditions were identical for both LAX-101 and placebo. The normal control group received neither KRG nor placebo. The aforementioned evaluations were performed at baseline and after 6 weeks.

Statistical analyses

Descriptive statistics were obtained for the ginseng and placebo groups. The two groups were compared using Student t test for continuous variables (age and education level) and by Chi-square test for categorical variables. Mixed model analyses were conducted to assess improvement in measures after 6 weeks of treatment to determine the group effect and group by time effect. For all analyses, two-sided significance was set at p < 0.05. Statistical analyses were performed using SPSS version 24 software (IBM SPSS Statistics, United States).

Results

The two groups showed no significant baseline differences in age, sex, education levels, body mass index (BMI), systolic and diastolic blood pressure, heart rate, alcohol intake and smoking status, BDI, or SRI (Table 1).
Table 1

Comparisons of basic characteristics between Korean Red Ginseng and placebo groups

VariablesKorean Red Ginseng group (n = 32)
Placebo group (n = 31)
Statistics t or χ2p
MeanSDMeanSD
Age39.5912.3641.2911.730.560.58
Sex (M)52.8%47.2%0.130.72
Education level (years)3.560.843.610.760.250.80
BMI22.893.6622.582.950.370.71
SBP127.1614.23123.1013.641.160.25
DBP79.289.1975.749.011.540.13
Heart rate77.4212.6874.397.931.130.26
Alcohol consumption, g/wk50.0392.8559.9799.030.410.68
Smoking, pack-year6.0919.415.6615.170.100.92
BDI20.448.9019.879.320.250.81
SRI56.8825.2654.6131.760.310.76

BDI, Beck Depression Inventory; BMI, body mass index; DBP, diastolic blood pressure; HR, heart rate; SBP, systolic blood pressure; SD, standard deviation; SRI, Stress Response Inventory.

Comparisons of basic characteristics between Korean Red Ginseng and placebo groups BDI, Beck Depression Inventory; BMI, body mass index; DBP, diastolic blood pressure; HR, heart rate; SBP, systolic blood pressure; SD, standard deviation; SRI, Stress Response Inventory. Fifty-five of the randomized participants (87.3%; 28 in the treatment group, 27 in the placebo group) completed the full 6 weeks of treatment. There was no significant difference in dropout rates between the groups (p > 0.05). No significant differences were observed regarding psychological measures (Table 2). In the cognitive function test (Table 3), an interaction effect of group by time was detected between the two groups for correct response time although it did not reach statistical significance (F = 3.84, p = 0.056). The KRG group showed a shorter correct response time after 6 weeks in visually controlled CPT, whereas the placebo group had longer correct response time at study endpoint.
Table 2

Comparison of psychological distress between Korean Red Ginseng and placebo groups after 6 weeks of treatment

VariablesKorean Red Ginseng group (n = 32)
Placebo group (n = 31)
Group effect
Group by time effect
Baseline6 weeksBaseline6 weeksFpFp
Profile of Mood States score (K-POMS) [mean (SD)]
 Total score98.59 (37.33)87.55 (36.77)71.71 (30.18)66.35 (32.39)1.170.2870.110.737
 Depression18.59 (9.43)15.65 (10.45)9.00 (7.19)10.00 (8.65)0.210.6530.890.352
 Vigor24.65 (2.38)27.06 (2.98)24.25 (2.20)23.20 (2.75)0.760.3890.400.531
 Anxiety14.71 (2.10)7.59 (1.86)11.95 (1.93)8.15 (1.72)0.410.5250.640.431
 Anger14.12 (9.57)9.47 (9.81)12.70 (8.30)7.95 (8.39)0.450.5070.010.980
 Fatigue18.35 (7.39)13.00 (7.52)15.90 (7.31)11.70 (7.59)1.180.2860.110.743
 Confusion8.18 (4.89)5.59 (3.18)7.10 (4.71)5.35 (4.84)0.390.5390.160.688
Perceived Stress Scale (PSS) [mean (SD)]
 Total score17.52 (4.14)14.00 (6.26)18.26 (4.21)15.81 (6.33)1.510.2240.280.600
 Positive9.04 (2.72)8.44 (3.90)9.11 (2.64)8.59 (4.25)0.020.8810.0040.949
 Negative8.48 (2.82)5.56 (4.04)9.15 (3.61)7.22 (3.97)2.250.1400.660.420
Sheehan Disability Scale (SDS) [mean (SD)]
 Total score10.38 (7.72)6.54 (5.18)11.96 (6.90)9.70 (7.56)2.410.1270.490.487
 Occupational3.33 (2.58)2.63 (1.97)3.60 (2.84)3.64 (2.66)1.220.2750.740.395
 Family3.17 (2.75)2.75 (2.03)3.76 (2.40)3.32 (2.32)0.930.339<0.010.971
 Interpersonal2.62 (2.48)1.96 (1.69)4.25 (2.36)4.00 (2.34)1.960.0070.690.411

SD, standard deviation.

Table 3

Comparison of cognitive measures between Korean Red Ginseng and placebo groups after 6 weeks of treatment

VariablesKorean Red Ginseng group (n = 32)
Placebo group (n = 31)
Group effect
Group by time effect
Baseline6 weeksBaseline6 weeksFpFp
Visually controlled continuous performance test (CPT) [mean (SD)]
 Number of correct response59.68 (8.16)61.72 (3.97)60.96 (5.97)61.75 (1.82)0.290.5940.390.538
 Omission error3.24 (8.19)1.08 (3.00)2.04 (5.97)1.25 (1.82)0.200.6600.460.500
 Commission error 10.56 (1.81)0.60 (2.06)2.96 (8.35)1.46 (4.64)1.720.1971.360.249
 Commission error 22.52 (10.95)0.36 (0.64)2.17 (9.36)0.54 (0.88)<0.010.9530.030.857
 Correct response time0.455 (0.10)0.439 (0.09)0.461 (0.10)0.475 (0.10)0.750.3933.840.056
Auditory controlled CPT [mean (SD)]
 Number of correct response60.48 (2.49)59.56 (3.87)59.38 (4.34)58.46 (4.63)1.470.232<0.010.998
 Omission error2.52 (2.49)3.24 (3.64)3.63 (4.34)4.54 (4.63)1.820.1840.020.879
 Commission error 11.88 (1.81)1.92 (2.00)3.88 (7.01)3.75 (5.48)2.420.1270.030.860
 Commission error 20.16 (0.37)0.12 (0.33)1.67 (6.30)0.21 (0.51)1.580.2151.260.268
 Correct response time0.659 (0.09)0.649 (0.09)0.674 (0.09)0.647 (0.08)0.610.4371.150.290

SD, standard deviation.

Comparison of psychological distress between Korean Red Ginseng and placebo groups after 6 weeks of treatment SD, standard deviation. Comparison of cognitive measures between Korean Red Ginseng and placebo groups after 6 weeks of treatment SD, standard deviation. In the blood measures (Table 4), a significant interaction effect of group by time was observed for triglyceride levels (F = 4.11, p = 0.048). The KRG group had greater triglyceride levels at study endpoint. However, the increased triglyceride level remained within the normal range, suggesting no harmful cardiovascular side effects. The number of participants whose triglyceride level exceeded normal limit (>200 mg/dL) was not significantly different between two groups (χ2 = 0.25, p = 0.61). Furthermore, a significant group effect and the interaction effect of group by time with a trend toward significance were detected in epinephrine levels: The KRG group showed a trend to decreasing epinephrine after treatment, whereas the placebo group showed increased epinephrine. No significant differences were observed in the other blood measures.
Table 4

Comparison of blood parameters between Korean Red Ginseng and placebo groups after 6 weeks of treatment

VariablesKorean Red Ginseng group (n = 32)
Placebo group (n = 31)
Group effect
Group by time effect
Baseline6 weeksBaseline6 weeksFpFp
Lipid battery [mean (SD)]
 HDL (mg/dL)62.66 (17.23)60.65 (17.78)63.58 (15.47)65.63 (17.22)0.670.421.870.18
 LDL (mg/dL)103.59 (28.44)110.92 (26.62)111.45 (31.61)105.75 (25.71)0.230.632.530.12
 Triglyceride (mg/dL)117.97 (67.51)149.65 (81.68)124.07 (68.83)111.21 (54.26)0.380.544.110.048*
 Total cholesterol (mg/dL)176.03 (30.73)185.73 (26.78)187.26 (31.43)179.50 (24.44)0.590.453.650.06
Catecholamine [mean (SD)]
 Norepinephrine (pg/dL)296.48 (139.40)307.21 (177.87)289.83 (119.15)314.24 (119.45)0.0020.970.210.65
 Epinephrine (pg/dL)29.17 (1.72)27.87 (1.91)30.60 (1.80)35.00 (2.02)4.350.043*2.960.093
Interleukin (IL) [mean (SD)]
 IL-1β0.64 (0.52)0.50 (0.53)1.38 (0.51)0.96 (0.53)0.680.410.880.36
 IL-20.87 (0.87)1.36 (0.88)1.78 (0.85)1.34 (0.90)0.140.711.430.24
 IL-40.47 (0.38)0.79 (0.40)0.73 (0.36)1.20 (0.43)0.560.460.050.82
 IL-60.71 (0.48)1.38 (0.50)0.82 (0.50)0.59 (0.55)0.410.530.940.34
 IL-101.07 (1.79)1.09 (2.08)3.59 (1.79)0.96 (2.28)0.350.560.460.50
 IL-121.73 (1.24)4.56 (1.29)0.51 (1.21)0.48 (1.41)3.710.0591.430.24
 IFN-α3.18 (1.57)6.08 (1.75)0.78 (1.55)1.27 (1.90)3.520.0650.700.41
 TNF-α8.98 (1.70)11.08 (1.95)10.65 (1.70)9.04 (2.14)0.080.931.240.27
C-reactive protein (mg/dL) (mean (SD)0.14 (0.25)0.10 (0.15)0.07 (0.09)0.07 (0.08)1.680.200.840.36
Fasting blood sugar (mg/dL) (mean (SD)114.19 (47.87)123.65 (52.42)104.73 (14.36)107.42 (34.19)1.290.260.560.81
HbA1c (mean (SD)5.38 (0 .31)5.33 (0.35)5.47 (0.38)5.31 (0.34)2.680.110.950.34

HbA1c, hemoglobin A1C; HDL-C, high-density lipoprotein-cholesterol; IFN, interferon; IL, interleukin; LDL-C, low-density lipoprotein-cholesterol; SD, standard deviation; TNF-α, tumor necrosis factor-alpha.

Linear mixed model analysis *p < 0.05, † Generalized estimating equation.

Comparison of blood parameters between Korean Red Ginseng and placebo groups after 6 weeks of treatment HbA1c, hemoglobin A1C; HDL-C, high-density lipoprotein-cholesterol; IFN, interferon; IL, interleukin; LDL-C, low-density lipoprotein-cholesterol; SD, standard deviation; TNF-α, tumor necrosis factor-alpha. Linear mixed model analysis *p < 0.05, † Generalized estimating equation. Because epinephrine is involved in triglyceride hydrolysis, we additionally evaluated the correlation between epinephrine and triglyceride levels after adjusting for age and BMI (Table 5). The epinephrine level was significantly associated with triglyceride levels (β = −0.087, p = 0.041). In the KRG group, the mean change of blood epinephrine level was consistently decreased depending on the mean changes of blood triglyceride level, whereas inconsistent patterns of change were observed in the placebo group (Fig. 2).
Table 5

Variation of plasma epinephrine level with age, BMI, and triglycerides: a multiple linear regression analysis

VariablesB coefficientSEp
1)Triglyceride, mg/dL−0.0870.0400.041*
BMI−0.4790.5160.361
Age, yr0.1100.1560.486

BMI, body mass index; SE, standard error.

Mean changes of triglyceride levels from baseline to 6 months after Korean Red Ginseng treatment.

Fig. 2

Mean change of blood epinephrine level after 6 weeks’ treatment depending on the triglyceride level changes.

Variation of plasma epinephrine level with age, BMI, and triglycerides: a multiple linear regression analysis BMI, body mass index; SE, standard error. Mean changes of triglyceride levels from baseline to 6 months after Korean Red Ginseng treatment. Mean change of blood epinephrine level after 6 weeks’ treatment depending on the triglyceride level changes.

Discussion

This is the first double-blind RCT to explore the biological evidence for an adaptogenic effect of KRG in individuals at high risk for stress. The results provide neurobiological evidence supporting an adaptogenic effect of KRG. The treatment group tolerated KRG very well, with a dropout rate similar to the placebo group. No significant improvement was detected with regard to subjective measures, including perceived stress level, mood status, and cognitive complaints, possibly because of the characteristics of the study participants. They all had highly stressful jobs, which were directly associated with greater psychological distress and high risk of mental illness. The 6-week treatment period might not have been long enough to produce an effect. In addition, a few studies suggest that high placebo effect was frequently observed in clinical trials of nutraceuticals [17] although evidence for this effect is mixed [18]. Expectations of a trial outcome [19] and treatment received [20] are likely to have a significant effect on the degree of placebo response. Blood parameters, however, suggested potential mechanisms associated with adaptogenic effect of KRG. The treatment group showed a significant increase in triglyceride levels (although still within the normal limit) and a trend toward decreased levels of epinephrine. Lower lipid levels have been associated with depression [21], impulsivity [22], [23], and suicidal attempts [24], [25] probably due to the impact of lipids on the structure and function of neuronal membranes [26]. In addition, epinephrine stimulates the sympathetic nervous system, which mediates the stress response. Interestingly, epinephrine levels in the KRG group showed a negative correlation with triglyceride levels (β = −0.087, p = 0.041); increased triglyceride levels were associated with decrease in epinephrine after adjusting for age and BMI. Epinephrine stimulated triglyceride hydrolysis in adipocytes [27]. In line with this finding, an animal study showed that saponin, a compound abundant in KRG, inhibited catecholamine secretion stimulated by cholinergic stimulation [28]. Chronic stress increases cortisol levels by activating the hypothalamic–pituitary–adrenal axis via catecholamine hormones including epinephrine. Increased cortisol level exacerbates the risk of metabolic syndrome associated with decreased urinary epinephrine output (20), suggesting complex interactions between lipid metabolism and the sympathoadrenal systems. In another study, individuals at risk of metabolic syndrome showed lower plasma epinephrine levels, which were negatively correlated with triglyceride (21). Taken together, the results suggest that KRG might stabilize the central nervous system, autonomic nervous system, and hypothalamic–pituitary–adrenal axis via complex effects on lipid metabolism and sympathoadrenal systems. Although subjective cognitive complaints were not improved, the KRG group also showed improvement in correct response time of visually controlled CPT, probably due to improved cognitive function. Ginsenosides, the triterpene glycosides (saponins), are the constituents found almost exclusively in ginseng. More than 100 ginsenosides have been isolated from P. ginseng, and protopanaxadiol and protopanaxatriol are the main structural components of the aglycone moiety of ginsenosides [29]. KRG is heat-processed P. ginseng. The processed red ginseng comprises unique constituents and is reported to exhibit antidiabetic, immune-modulating, anticancer, and antiinfection activities [30]. There are several caveats to be considered in the interpretation of the study findings. First, we evaluated limited numbers of biological markers. Therefore, it is premature to confirm the association between KRG and autonomic nervous system. Second, no significant difference was observed in subjective psychological distress between the KRG and placebo groups. As mentioned previously, strong placebo effects may occur in clinical trials of nutraceuticals, perhaps in part due to expectations on the part of study participants to receive nutraceutical therapy rather than placebo or other comparator [20]. Third, 6 weeks might not be enough to evaluate psychological changes induced by administration of Korean Red Ginseng. In particular, changes in other biological markers, particularly inflammatory cytokines, may also take as long as 8–12 weeks to manifest. Considering that most nutraceuticals are consumed for a long time, additional studies are needed to determine the long-term effect of KRG. Fourth, all study participants had very stressful professions, so their response to KRG may vary from that of individuals with less stressful jobs. Finally, cognitive function was not evaluated using a comprehensive test that evaluated a wide range of cognitive function. Notwithstanding these limitations, this study provides biological evidence that may be associated with an adaptogenic effect of KRG. In this randomized, double-blind RCT, KRG decreased epinephrine levels, which was associated with increased, but still normal, triglyceride levels. Decreased catecholamines and increased triglycerides may contribute to stabilization of the autonomic nervous system and neural membranes. KRG additionally improved the cognitive process. The study result suggests that KRG might play a role in autonomic nervous system, which is associated with its adoptogenic effect. Further studies are warranted to determine the appropriate treatment dosage and duration of KRG.

Conflicts of interest

All authors reported no conflict of interest.
  26 in total

Review 1.  The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach.

Authors:  Maurizio Fava; A Eden Evins; David J Dorer; David A Schoenfeld
Journal:  Psychother Psychosom       Date:  2003 May-Jun       Impact factor: 17.659

2.  The treatment of minor depression with St. John's Wort or citalopram: failure to show benefit over placebo.

Authors:  Mark Hyman Rapaport; Andrew A Nierenberg; Robert Howland; Christina Dording; Pamela J Schettler; David Mischoulon
Journal:  J Psychiatr Res       Date:  2011-05-31       Impact factor: 4.791

3.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

4.  Higher prevalence of depressive symptoms in middle-aged men with low serum cholesterol levels.

Authors:  P H Steegmans; A W Hoes; A A Bak; E van der Does; D E Grobbee
Journal:  Psychosom Med       Date:  2000 Mar-Apr       Impact factor: 4.312

5.  Pectic polysaccharides from Panax ginseng as the antirotavirus principals in ginseng.

Authors:  Seung-Hoon Baek; Jin Gyun Lee; Seo Young Park; Ok Nam Bae; Dong-Hyun Kim; Jeong Hill Park
Journal:  Biomacromolecules       Date:  2010-08-09       Impact factor: 6.988

6.  Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition.

Authors:  M I Geerlings; C Jonker; L M Bouter; H J Adèr; B Schmand
Journal:  Am J Psychiatry       Date:  1999-04       Impact factor: 18.112

7.  Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants.

Authors:  Marlene P Freeman; David Mischoulon; Enrico Tedeschini; Tracie Goodness; Lee S Cohen; Maurizio Fava; George I Papakostas
Journal:  J Clin Psychiatry       Date:  2010-06       Impact factor: 4.384

8.  Low cholesterol is a risk factor for attentional impulsivity in patients with mood symptoms.

Authors:  Alfonso Troisi
Journal:  Psychiatry Res       Date:  2010-11-27       Impact factor: 3.222

9.  Development of the somatic stress response scale and its application in clinical practice.

Authors:  Kyung Bong Koh; Joong Kyu Park; Sunghee Cho
Journal:  Yonsei Med J       Date:  2005-10-31       Impact factor: 2.759

10.  Serum cholesterol and impulsivity in a large sample of healthy young men.

Authors:  Flavio Pozzi; Alfonso Troisi; Marco Cerilli; A M Autore; C Lo Castro; D Ribatti; Gaetano Frajese
Journal:  Psychiatry Res       Date:  2003-10-15       Impact factor: 3.222

View more
  5 in total

1.  Effectiveness and Tolerability of Korean Red Ginseng Augmentation in Major Depressive Disorder Patients with Difficult-to-treat in Routine Practice.

Authors:  Kyung Ho Lee; Won-Myong Bahk; Soo-Jung Lee; Chi-Un Pae
Journal:  Clin Psychopharmacol Neurosci       Date:  2020-11-30       Impact factor: 2.582

Review 2.  Evolution of the adaptogenic concept from traditional use to medical systems: Pharmacology of stress- and aging-related diseases.

Authors:  Alexander G Panossian; Thomas Efferth; Alexander N Shikov; Olga N Pozharitskaya; Kenny Kuchta; Pulok K Mukherjee; Subhadip Banerjee; Michael Heinrich; Wanying Wu; De-An Guo; Hildebert Wagner
Journal:  Med Res Rev       Date:  2020-10-25       Impact factor: 12.944

3.  Korean Red Ginseng reduces chronic social defeat stress-induced mood disorders via N-methyl-D-aspartate receptor modulation in mice.

Authors:  Bo-Ram Lee; Ju-Hyun Lee; Yong-Hyun Ko; Jee-Yeon Seo; Kwang-Hyun Hur; Young-Jung Kim; Seon-Kyung Kim; Seong-Eon Kim; Seok-Yong Lee; Choon-Gon Jang
Journal:  J Ginseng Res       Date:  2019-11-07       Impact factor: 6.060

4.  The effect of ginsenosides on depression in preclinical studies: A systematic review and meta-analysis.

Authors:  Yunna Kim; Seung-Hun Cho
Journal:  J Ginseng Res       Date:  2020-09-04       Impact factor: 6.060

Review 5.  Ginsenoside and Its Therapeutic Potential for Cognitive Impairment.

Authors:  Hui Feng; Mei Xue; Hao Deng; Shiqi Cheng; Yue Hu; Chunxiang Zhou
Journal:  Biomolecules       Date:  2022-09-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.